INSTRUCTIONS FOR FILLING OUT FORM FDA 356h – APPLICATION TO MARKET A NEW OR ABBREVIATED NEW DRUG OR BIOLOGIC FOR HUMAN USE
(The field numbers below correspond to the numbered boxes on the Form FDA 356h)

NOTE: Please submit a new Form FDA 356h with each submission. Complete the pages of the form sequentially using continuation pages as needed. If continuation pages are not needed, click on the ‘Remove Continuation Page’ button at top/bottom of form.

Field 1: Enter the date the submission is being submitted to the FDA. The date entered should match the date of the cover letter for the submission.

Fields 2-6: APPLICANT INFORMATION
This section should include the name, street address, telephone and facsimile numbers of the person or legal entity submitting the application. For biologic products, the name of applicant in Field 2 is the name of the person or legal entity to whom the license will be issued. Enter the U.S. license number, if previously issued, in the appropriate field. Enter the name, street address, and telephone number of the person or legal entity authorized to represent a non-U.S. applicant in Field 6.

Fields 7-15: PRODUCT DESCRIPTION
This section should include all of the information necessary to identify the product that is the subject of this application or submission.

Field 7: Provide the six-digit application number. For application numbers less than six-digits, the application number should be preceded using zeros (i.e., for NDA 12345 enter 012345).

Field 8: Provide the four-digit supplement number with preceding zeros for supplement numbers that are less than four-digits (i.e., for Supplement 1 enter 0001).

Field 15: For original and efficacy supplemental applications only (including resubmissions to these application types), provide the indication(s) proposed within the application. Indicate if the proposed indication is for a rare disease (prevalence <200,000 U.S. patients). Indicate if the product proposed within the application (i.e. not the reference listed drug for an ANDA) has an FDA Orphan Drug Designation and if so; provide the six-digit Orphan Designation number. If the submission is not an original application or efficacy supplement, select ‘No’ in response to ‘Is this indication for a rare disease?’ Use the Continuation Page if there are more than one proposed indications for use by adding one indication per entry and providing rare disease/Orphan Drug Designation information for each entry, as applicable. If continuation pages are not needed, click on the ‘Remove Continuation Page’ button at top/bottom of form.

Fields 16-31: APPLICATION INFORMATION
Fields 16-18: Identify the appropriate application type.

Field 19: If the application is a 351(k) BLA, provide the name of the biological reference product that is the basis for the application and the holder of the licensed application.

Field 20: If the application is an ANDA or 505(b)(2) NDA, provide the name of the reference listed drug (ANDA) or listed drug(s) (505(b)(2) NDA) that is/are the basis for the application, the application number(s) for the listed drug(s), and indicate what type(s) of patent certification or statement described under 21 CFR 314.50(i) is provided within the application.

Field 21: Select one of the submission types listed or specify the type of submission under “Other” if otherwise not listed. See also 21 CFR 314.3(b).

Original: An application for which FDA has never issued an approval letter;

Labeling Supplement: A supplemental application for labeling changes to an approved product as described under 21 CFR 314.70 and 21 CFR 601.12 that does not otherwise qualify as another type of supplement (e.g., Efficacy, CMC, REMS);
**CMC Supplement**: A supplemental application for chemistry, manufacturing, and control (CMC) changes to an approved product as described under 21 CFR 314.70, 21 CFR 314.71, 21 CFR 314.72, and 21 CFR 601.12, including CMC supplements with corresponding labeling changes;

**Efficacy Supplement**: A supplemental application for changes to an approved product, including but not limited to, a new indication, a new dosage regimen or route of administration, a comparative efficacy claim naming another approved product, or a significant alteration in the patient population (e.g., a switch of marketing status from prescription to over-the-counter), or labeling or manufacturing changes requiring clinical data for approval;

**Annual Report**: See 21 CFR 314.81(b)(2) for NDAs and 21 CFR 601.12(d) for BLAs;

**Product Correspondence**: Any communication or general correspondence related to an application (e.g., routine administrative changes, donor re-entry requests, lot distribution reports, license reissuance requests, meeting requests) that is not an amendment to a pending application. Provide a description of the content or intent of the Product Correspondence in Field 25 (Reasons for the Submission);

**REMS Supplement**: A supplemental application proposing a new Risk Evaluation and Mitigation Strategy (REMS), REMS modification (including changes to a Medication Guide that is part of a REMS), or submission of a REMS assessment;

**Post Marketing Requirements or Commitments**: A submission containing information related to post marketing requirements or commitments (e.g., nonclinical protocol, final study report);

**Periodic Safety Report**: Periodic reports (Periodic Adverse Drug Experience Reports (PADERs)) of adverse drug or biological product experience as described under 21 CFR 314.80(c)(2), 21 CFR 314.98, and 21 CFR 600.80(c)(2), including those in Periodic Safety Update Report (PSUR) format;

**Other (specify)**: State the submission type if it is not one of the previous submission types listed above (e.g., formal dispute resolution request). If this box is checked, provide the Reasons for the Submission in Field 25.

**Field 22**: Select one of the submission sub-types listed. See also 21 CFR 314.3(b).

- **Presubmission**: Information submitted prior to the submission of a complete original application (e.g., submission of partial application (rolling submission));

- **Amendment**: A submission to a pending original application, or pending supplemental application, including responses to Information Request letters, Discipline Review letters, or other FDA communications. Amendments also include submissions that contain additional supportive material intended to augment or revise information previously submitted in a submission type listed under Field 21 (e.g., amendment to an annual report);

- **Initial submission**: A submission type under Field 21 that has never before been submitted (excluding presubmissions);

- **Resubmission**: A complete response to an action letter, or submission of an original application that has been the subject of a withdrawal before FDA action or a refusal to file action.

**Field 23**: Select the appropriate type of supplemental application, if applicable.

- **CBE (Changes Being Effected)**: A supplemental application proposing certain changes for which distribution of the product made using the change(s) can occur upon FDA receipt of the application as described under 21 CFR 314.70(c)(6) and 21 CFR 601.12(c)(5);

- **CBE-30 (Changes Being Effected in 30 Days)**: A supplemental application proposing certain changes requiring submission at least 30 days prior to distribution of the product made using the change(s) as described under 21 CFR 314.70(c) and 21 CFR 601.12(c);

- **Prior Approval (PA)**: A supplemental application proposing a major change for which distribution of the product made using the change(s) cannot occur prior to FDA approval as described under 21 CFR 314.70(b) and 21 CFR 601.12(b).
Field 24: If the submission identified in Field 21 of this form contains data only from pediatric studies, select 'Yes'. If the submission does not contain data from pediatric studies, or is an original application or efficacy supplement that contains data from both adult and pediatric studies, select 'No'.

Field 25: This section should contain a brief explanation of the contents of, or rationale for, the submission (e.g., “manufacturing change from roller bottle to cell factory” or “response to Information Request Letter of mm/dd/yy” or “pediatric exclusivity determination request” or “to fulfill a Subpart H postmarketing requirement”).

Field 26: Select the appropriate Proposed Marketing Status.

Field 27: Indicate whether the submission contains only Paper, both Paper and Electronic, or only Electronic Media (e.g., electronic media or electronic submissions sent via the Electronic Submissions Gateway (ESG)).

Field 28: Enter the number of volumes, including electronic media, contained in the archival copy of this submission.

Field 29: For original (initial) applications, efficacy supplements, CMC supplements, and resubmissions to these submission types, this section should include complete information on the locations of all manufacturing, packaging, and control sites for both drug substance and drug product. Establishment information on bioequivalence testing sites, excipient testing sites, and container/closure manufacturing and testing establishments is not required in Field 29. For presubmissions and amendments to these submission types, complete establishment information should be provided in this section when applicable (e.g., an amendment that describes changes to previously submitted establishment information; an amendment that adds or removes an establishment; a presubmission that includes CMC information including establishment information). For each site, please include the establishment name, address, registration (FEI) number, Master File (MF; Drug Master File (DMF) or Biologic Master File (BMF)) number (for facilities used under a MF), and establishment DUNS number. Indicate whether or not the establishment is new to the application. New establishments will have by default a ‘pending’ status. If it is not a new establishment, indicate its current status (e.g., active, inactive, or withdrawn) in the appropriate box. Also provide the name, address, phone number, fax number and email address for the contact at the site. In the section “Manufacturing Steps, and/or Type of Testing”, provide a brief description of the specific manufacturing steps and/or type of testing (e.g., final dosage form, stability testing) conducted at the site (i.e., describe the type(s) of assays or testing completed). Indicate whether the site is ready for inspection, or if not, when it will be ready.

Please note that, when applicable, the complete establishment description is requested under Field 31, item 15.

Use the Continuation Page as needed. If continuation pages are not needed, click on the ‘Remove Continuation Page’ button at top/bottom of form.

Field 30: This section should contain a list of all Biologics License Applications (BLAs), Investigational New Drug Applications (INDs), New Drug Applications (NDAs), Premarket Approval Applications (PMAs), Premarket Notifications (510(k)s), Investigational Device Exemptions (IDEs), and/or DMFs/BMFs that are cross-referenced in the current application. Use the Continuation Page as needed. If continuation pages are not needed, click on the ‘Remove Continuation Page’ button at top/bottom of form.

Field 31: This section contains items 1 through 20 which is a checklist that should be used to indicate the types of information contained within a particular application or submission. Check all that apply. A complete index or table of contents should immediately follow the Form FDA 356h and, if applicable, a User Fee Cover Sheet (Forms FDA 3397, 3792, or 3794). Note that the CFR references are provided for most items in order to indicate what type of information should or must be submitted in each section. For further information, the applicant may consult the guidance documents that are available from the Agency.

Fields 32-39: CERTIFICATION

Enter the name and title, telephone number, facsimile number, email address, and street address of the applicant’s Responsible Official in Fields 32-37 of the form. This person is responsible for certifying compliance with applicable laws and regulations. The authorized U.S. agent named in Field 6 of the form may also act as the applicant’s Responsible Official. The form must be signed in Field 38 by the applicant, or the applicant’s attorney, agent, or other authorized official. 21 CFR 601.2(a). If the person signing the form in Field 38 does not reside or have a place of business within the United States, the form must be countersigned in Field 39 by an attorney, agent, or other authorized official who resides or maintains a place of business within the United States. 21 CFR 314.50(a)(5).